73 results about "Fasting blood glucose level" patented technology

The invention discloses an abnormal fasting blood glucose level early-warning method based on an integrated learning fusion model. With combination of individual physical examination data of blood routine examination, liver function, blood fat, and renal function and the like, a fasting blood glucose level is predicted by fusing a gradient regression tree, a random forest, and a linear regressionmodel and the like based on an integrated learning method. The prediction model is trained by using lots of training data, so that the accuracy, universality and robustness of the prediction model areimproved. Fasting blood glucose level prediction is carried out on timely an individual without fasting blood glucose checking, so that the high-diabetes-risk patient is warned early and effectively.

The invention discloses a total triterpenoid extract of inonotus obliquus with a hypoglycemic function, which is prepared through the following steps: (1) crushing and sieving inonotus obliquus, adding ethanol aqueous solution for immersion, carrying out ultrasonic extraction, separating the supernatant, and concentrating and drying the supernatant, thereby obtaining ethanol extract; (2) dispersing the ethanol extract into distilled water, oscillating and extracting with petroleum ether, and separating the extract from water-phase residues generated in extraction; and (3) oscillating and extracting the water-phase residues with n-butanol, separating the extract, mixing, concentrating and drying, thereby obtaining the total triterpenoid extract of the inonotus obliquus with the hypoglycemic function, wherein the content of the triterpenoid is 70-300mg/g. the total triterpenoid extract of the inonotus obliquus with the hypoglycemic function provided by the invention can obviously reduce the fasting blood glucose level of mouse with hyperglycemia, can significantly ease the diabetes symptoms of the mouse with hyperglycemia, and has no significant toxicity to major organs.

The invention provides a preparation method and application of total flavone and total polysaccharide in cyclocarya paliurus leaves. The method comprises the steps of taking cyclocarya paliurus leavesas raw materials, executing extraction by an ethanol-water solvent, executing extraction by an organic solvent, executing elution by a chromatographic column and by macroporous resin to obtain totalflavone, conducting extraction on cyclocarya paliurus leaf dregs by hot water, executing precipitation, removing protein, and adsorbing impurities by macroporous resin to obtain total polysaccharide.Studies show that the total triterpenes, the total flavones, the total polysaccharides and their composition prepared by the method can effectively increase glucose uptake of 3T3-L1 adipocytes, obviously reduce the fasting blood glucose level of the hereditary diabetes db/db mice, has antidiabetic activity, and can be used for preparing products such as antidiabetic medicines, health foods, functional foods and the like for reducing blood sugar. The invention develops the comprehensive preparation method of total flavones and total polysaccharides in cyclocarya paliurus leaves and applicationof the mehtod in resisting diabetes, and provides a basis and a new application direction for popularization, utilization and deep processing of traditional Chinese medicinal materials and new food raw materials.

The invention discloses a use of ocean collagen peptide used in preparation of blood-glucose medicine, hypoglycemic health food or hypoglycemic food, which is characterized by high absorption, fast absorption, low viscosity, and good water-solubility etc. Experiment proves that the ocean collagen peptide given to a little mouse can lower alloxan hyperglycosemia of fasting blood-glucose level of a big mouse. Meanwhile, sugar tolerance of a hyperglycemia big mouse is improved, which indicates that the ocean collagen peptide has hypoglycemic action.

The invention discloses a Plantain seed extract and application thereof. The Plantain seed extract is acquired by reflux extraction of Plantain seed with 2-6 volume times of 60-90vol% ethanol aqueous solution 2-6 times. The Plantain seed extract contains acteoside, isoacteoside, geniposidic acid, ferulic acid, and Cheqiansu A and Cheqiansu B. In-vivo experiments show that the Plantain seed extract provided by the invention can promote glucose consumption and has lower toxicity to cells; and simultaneously in-vitro experiments show that the Plantain seed extract can significantly increase serum insulin level and reduce fasting blood-glucose level, presents good medicinal value in treatment of diabetes; therefore, the Plantain seed extract can be used in the preparation of pharmaceutical medicaments for treating diabetes singly or together with a pharmaceutically acceptable composition composed of a drug carrier.

The invention relates to application of total saponins in unripe siraitia grosvenorii fruit extract in preparation of an assistant hypoglycemic drug. Extract containing the total saponins with the content by weight of 60%-90% is extracted from unripe siraitia grosvenorii fruit with the growing period of 30 days-80 days, one of the effective ingredients mogroside II and mogroside III in the total saponins or a mixture of the effective ingredients mogroside II and mogroside III in the total saponins inhibits the activity of alpha-glucosidase in vitro and in vivo, the fasting blood-glucose level and the postprandial blood glucose level of a type-II diabetic mouse are lowered, and the activity of the insulin resistance index is reduced; in addition, new application of the total saponins in preparation of food or the drug for assisting in treating insulin resistance and type-II diabetes mellitus is achieved.

The invention relates to the technical field of microbes, and discloses a probiotic composition and application thereof. The probiotic composition consists of bifidobacterium adolescentis CCFM8630, lactobacillus reuterii CCFM8631 and lactobacillus rhamnosus CCFM1044, the effect of relieving metabolic syndromes is significantly better than that of CCFM8630 or CCFM8631 used alone and in combination,especially in fields of reducing an epididymal fat content, reducing a fasting blood glucose level, reducing a glucose tolerance curve lower area, lowering a serum low-density lipoprotein and total cholesterol content, increasing the liver antioxidant capacity and reducing a serum IL-1beta content, the decrease or increase of the composition is increased by 9.62%-769.62% compared with a single bacteria or double bacteria combination formula, and the triple bacteria combination can achieve significant synergy.

The invention discloses an effective fraction of plantain seeds, as well as a preparation method and an application thereof. The effective fraction of plantain seeds is obtained by separating and purifying a plantain seed ethanol extract with a macroporous resin and contains hispidulin A and acteoside; and the weight ratio of hispidulin A to acteoside ranges from 1:1 to 1:5 and the sum weight of hispidulin A and acteoside accounts for 40% to 80% of the total weight of the effective fraction. The effective fraction of plantain seeds, disclosed by the invention, can promote the secretion of insulin and reduce fasting blood-glucose levels and can also effectively reduce blood pressure in animals and reduce blood plasma angiotensin II level, shows good medicinal values in treatment of diabetes and hypertension, and can be used alone or in combination with pharmaceutically-acceptable carriers to prepare pharmaceutical formulations for treating diabetes and/or hypertension.

This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as “aP2”) for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.

The invention relates to a microbial composition for preventing or treating type II diabetes mellitus as well as a preparation method and application thereof. The microbial composition for preventing or treating type II diabetes mellitus comprises a bifidobacterium longum BL21 strain and a lactobacillus rhamnosus LRa05 strain. The microbial composition can obviously reduce the body weight of a patient with type II diabetes mellitus; the levels of ALT, AST and the like in the serum of the type II diabetes mellitus patient are obviously reduced; the levels of serum inflammatory factors such as TNF-alpha and IL-1beta are reduced; the increased fasting blood glucose level and the area under the curve in the oral glucose tolerance test are significantly reduced; the DX-4000-FITC level of the plasma at the time of 2.5 hours is obviously reduced and the plasma LPS level is obviously reduced. Therefore, the microbial composition has a great application prospect in preparation of medicines, foods or health-care products for preventing, treating and relieving type II diabetes mellitus.

A subject is prescribed short and long acting insulin medicament regimens. When a qualified fasting event occurs, the basal insulin sensitivity estimate of the subject is updated using (i) an expected fasting blood glucose level based upon the long acting insulin medicament dosing specified by the long acting regimen during the fasting event, (ii) glucose measurements contemporaneous with the fasting event and (iii) a prior insulin sensitivity factor. A basal insulin sensitivity factor curve is calculated from the updated basal insulin sensitivity estimate. A bolus insulin sensitivity estimate of the subject is updated upon occurrence of a correction bolus with a short acting insulin medicament using (i) an expected blood glucose level based upon the correction bolus, (ii) glucose measurements after occurrence of the correction bolus, and (iii) a prior insulin sensitivity factor. A bolus insulin sensitivity factor curve is calculated from the updated bolus insulin sensitivity estimate.

The invention discloses a function of tumor progress site 2 in treatment of fatty liver and type 2 diabetes as well as an application thereof. According to the invention, TPL2 gene knockout mice and wild type mice are taken as the experiment objects, through a high-fat diet-induced obesity mice model, the result shows that compared with the wild type C 57 mice, body weight of the TPL2 gene knockout mice is mitigated, the fasting blood glucose level is lower than that of a control group WT mice, and the hepatic dysfunction is obviously mitigated. Through intraperitoneal glucose tolerance experiment, the endurance of the TPL2 gene knockout mice on glucose is obviously enhanced. the mice liver tissue cholesterol content change result instructs that TPL2-KO mice fatty liver pathology of a HFD group (High fat diet) is obviously mitigated, and the lipid accumulation is obviously reduced. TPL2 can be taken as a drug target for treating fatty liver and/or type 2 diabetes, and its inhibitor can be used for preparing a drug to treating fatty liver and/or type 2 diabetes.

The invention relates to the technical field of microorganisms, in particular to a lactobacillus plantarum HOM3201 strain, a viable bacterium preparation containing the lactobacillus plantarum HOM3201 strain as well as a preparation method and application of the lactobacillus plantarum HOM3201 strain. The preservation number of the lactobacillus plantarum HOM3201 strain is CGMCC (China General Microbiological Culture Collection Center) No. 22700. The lactobacillus plantarum HOM3201 strain can significantly reduce the fasting blood glucose level of insulin-resistant glucose/lipid metabolism disorder model rats, increase the tolerance of the body to glucose, and reduce the insulin resistance index.

The present invention refers to a data management unit for supporting health control and a corresponding medical device comprising a data storage (130) adapted to store a plurality of measurement values of a physiological parameter, for example the fasting blood glucose level, and for each measurement value an associated time stamp and a trend indicator (164), wherein the trend indicator is adapted to indicate different trend categories, for example an increasing trend, a steady trend and a decreasing trend, preferably as a respective visible sign (201,202) on a display (162) and/or as a respective audible signal by a loudspeaker, a processor (140) adapted to select a first group of measurement values and a second group of measurement values from the plurality of measurement values of the data storage (130) such that the associated time stamp of each of the measurement values of the first group is in a predefined first time interval and the associated time stamp of each of the measurement values of the second group is in a predefined second time interval, wherein the second time interval is more recent than the first time interval, wherein the processor is further adapted to calculate a first mean value as a median from the first group of measurement values and a second mean value from the second group of measurement values, wherein the processor (140) interacts with the trend indicator (164) such that the trend indicator (164) indicate one of the different trend categories, for example the increasing trend, the steady trend or the decreasing trend, dependent on a result of a comparison of the second mean value to the first mean value. Additionally, the invention refers to a corresponding method and a computer program for indicating a trend, and to a corresponding computer program product.

The invention discloses functions and application of an LILRB4 (leukocyte immunoglobulin-like receptor B4) gene to treatment on fatty liver diseases and diabetes. By taking LILRB4 gene knock-out mice and wide type C57 mice as experimental subjects and through high fat diet (HFD) induced obesity mouse models, result shows that compared with the wild type (WT) C57 mice, the weight of the LILRB4-KO mice is not remarkably changed after HFD, but the fasting blood-glucose level of the LILRB4-KO mice is higher than that of the WT mice in the control group and the liver function of the LILRB4-KO mice is remarkably worse than that of the WT mice. Intraperitoneal injection glucose tolerance experiments show that the glucose tolerance of the LILRB4-KO mice is remarkably weakened. The liver weight and liver/weight ratio, the lipid component pathological staining result and the like indicate that the fatty liver lesion of the LILRB4-KO mice in the HFD group is remarkably deteriorated and the lipid accumulation is remarkably increased. Therefore, the LILRB4 can serve as a target for screening medicines for treating the fatty liver and/or the type 2 diabetes mellitus, and an accelerant of the LILRB4 can be used for preparing the medicines for treating the fatty liver and/or the type 2 diabetes mellitus.

The invention provides hawthorn health food assisting regulating blood sugar level. The hawthorn health food is formed by performing reasonable compounding on hawthorn alcohol extract and a water extract composition of corn stigma, siraitia grosvenorii and lycium barbarum, and specially comprises the following components in parts by weight: 50 to 100 parts of the hawthorn alcohol extract, and 10 to 50 parts of a water extract composition of the corn stigma, siraitia grosvenorii and lycium barbarum, wherein the water extract composition is prepared from the corn stigma, siraitia grosvenorii andlycium barbarum according to the mass ratio being (20-30): (5-10): (5-10). The hawthorn health food obviously reduce the fasting blood-glucose level, and compared with the prior art, the food has equivalent or better efficacy of assisting regulating blood sugar level, and produces the effect of synergistic interaction. Meanwhile, as all raw materials belongs to medicinal and edible materials, thefood has the characteristics of rice resources, wide distribution, low price and high availability, and the food is simple in production process, low in operation cost, more suitable for common consumer groups, and good in safety.

The invention discloses the function and application of three-structural-domain protein 8 in treating non-alcoholic fatty liver disease and II type diabetes mellitus. TRIM8 gene knockout mice and wild type C57 mice are used as experimental subjects, by means of a high-fat diet induced fat mice model, the result indicates that compared with the wild type C57 mice, the weight of the TRIM8 gene knockout mice is reduced, the fasting blood-glucose level of the TRIM8 gene knockout mice is lower than that of control group WT mice, and hepatosis is obviously relieved. Mouse liver weight, the liver/weight ratio and a lipid component pathological staining result show that fatty liver pathological changes of the TRIM8-KO mice having high-fat diet are obviously relieved, and lipid accumulation is remarkably reduced. Therefore, TRIM8 can serve as a drug target for screening and treating fatty liver disease and/or II type diabetes mellitus, and inhibitor of TRIM8 can be used for preparing a drug for treating fatty liver disease and/or II type diabetes mellitus.

Compositions and related methods using soy albumin to provide a variety of health-related benefits. University controlled studies demonstrated that an effective amount of soy albumin provided to a human daily for eight weeks provided unexpected synergistic results that provided a variety of health-related benefits. In particular, eight weeks of supplementation with soy albumin alone and in combination with fenugreek, phaseolamine, and bicarbonate resulted in 1) weight loss, 2) reduced total cholesterol levels, 3) reduces LDL cholesterol levels, 4) increased HDL or good cholesterol levels, 5) improved total cholesterol/HDL ratio, 6) improved LDL/HDL ratio, ratio, 7) reduced triglyceride levels, 8) increased serum serotonin levels, 9) decreases fasting blood glucose levels, and 10) prevention, improvement or treatment of Syndrome X or the cardiovascular or metabolic factors that cause Syndrome X.

Nuclear Transport Modifiers such as cSN50 and cSN50.1, afford in vivo islet protection following a 2-day course of intense treatment in autoimmune diabetes-prone, non-obese diabetic (NOD) mice, a widely used model of Type 1 diabetes (T1D), which resulted in a diabetes-free state for one year without apparent toxicity and the need to use insulin. cSN50 precipitously reduces the accumulation of islet-destructive autoreactive lymphocytes while enhancing activation-induced cell death of T and B lymphocytes derived from NOD mice. cSN50 attenuated pro-inflammatory cytokine and chemokine production in immune cells in this model of human T1D. cSN50 also provides cytoprotection of beta cells, therefore preserving residual insulin-producing capacity. Because intracellular delivery of a Nuclear Transport Modifier peptide such as cSN50 and cSN50.1 can result in lowering of fasting blood glucose levels and may ameliorate (e.g., reduce, eliminate) insulin resistance, the compositions, methods and cells described herein can also be used for treating Type 2 diabetes (T2D).